NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Syros Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.48 +0.24 (+3.31 %) (As of 01/27/2020 12:09 PM ET) Add Compare Today's Range$7.08Now: $7.48▼$7.5250-Day Range$4.52MA: $6.83▼$9.2152-Week Range$4.45Now: $7.48▼$11.93Volume10,605 shsAverage Volume307,462 shsMarket Capitalization$317.45 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS Previous Symbol CUSIPN/A CIK1556263 Webhttp://www.syros.com/ Phone617-744-1340Debt Debt-to-Equity Ratio0.20 Current Ratio4.92 Quick Ratio4.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.05 million Price / Sales154.85 Cash FlowN/A Price / Cash FlowN/A Book Value$2.34 per share Price / Book3.20Profitability EPS (Most Recent Fiscal Year)($1.91) Net Income$-62,280,000.00 Net Margins-3,115.38% Return on Equity-84.49% Return on Assets-60.09%Miscellaneous Employees76 Outstanding Shares42,440,000Market Cap$317.45 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive SYRS News and Ratings via Email Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SYRS Rates by TradingView Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals Inc (NASDAQ:SYRS) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.01. The business earned $0.56 million during the quarter, compared to analyst estimates of $0.43 million. Syros Pharmaceuticals had a negative return on equity of 84.49% and a negative net margin of 3,115.38%. View Syros Pharmaceuticals' Earnings History. When is Syros Pharmaceuticals' next earnings date? Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals. What price target have analysts set for SYRS? 7 equities research analysts have issued 1-year price targets for Syros Pharmaceuticals' stock. Their forecasts range from $9.00 to $18.00. On average, they anticipate Syros Pharmaceuticals' share price to reach $13.83 in the next twelve months. This suggests a possible upside of 84.9% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals. What is the consensus analysts' recommendation for Syros Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals. Has Syros Pharmaceuticals been receiving favorable news coverage? Press coverage about SYRS stock has been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Syros Pharmaceuticals. Are investors shorting Syros Pharmaceuticals? Syros Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totalling 2,340,000 shares, an increase of 30.0% from the December 31st total of 1,800,000 shares. Based on an average trading volume of 479,200 shares, the days-to-cover ratio is currently 4.9 days. Currently, 7.6% of the company's stock are sold short. View Syros Pharmaceuticals' Current Options Chain. Who are some of Syros Pharmaceuticals' key competitors? Some companies that are related to Syros Pharmaceuticals include IGM Biosciences (IGMS), Madrigal Pharmaceuticals (MDGL), ZEALAND PHARMA/S (ZEAL), Myovant Sciences (MYOV), Endonovo Therapeutics (ENDV), Athenex (ATNX), Rocket Pharmaceuticals (RCKT), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), Opko Health (OPK), Phibro Animal Health (PAHC), Dermira (DERM), Karyopharm Therapeutics (KPTI), NextCure (NXTC) and Revance Therapeutics (RVNC). What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Global Blood Therapeutics (GBT), Galmed Pharmaceuticals (GLMD), ImmunoGen (IMGN) and Viking Therapeutics (VKTX). Who are Syros Pharmaceuticals' key executives? Syros Pharmaceuticals' management team includes the folowing people: Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)Dr. David A. Roth, Chief Medical Officer (Age 56)Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $7.48. How big of a company is Syros Pharmaceuticals? Syros Pharmaceuticals has a market capitalization of $317.45 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals. What is Syros Pharmaceuticals' official website? The official website for Syros Pharmaceuticals is http://www.syros.com/. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected] MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 309 (Vote Outperform)Underperform Votes: 280 (Vote Underperform)Total Votes: 589MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: What is included in the gross domestic product?
